Asthma Market to Witness the Highest Growth Globally in Coming Years
Pramod KmrDecember 20, 2018Asthma Market, Asthma Market Share, Asthma Market Size, Demand, Growth, Growth Opportunities, Outlook, Trends
No comments
Asthma is a respiratory condition, where the airways become
inflamed and narrow, which can cause a serious and incurable condition if left
untreated. Breathlessness, wheezing and coughing are some of the symptoms of
asthma and it can be controlled by avoiding triggers and with the help of drug
therapy. Environmental triggers may vary from consumer to consumer but it can include
exercise, smoke, cold air and other allergens such as pollen, dust mites, and
infections. The wheezing in asthma begins when the chemicals present in the
lungs overreact to the dust mites, cold air and exercise.
According to Centers for Disease Control and Prevention
(CDC), asthma is an ordinary chronic airway disorder which is characterized by
swelling of air passages that convey air from mouth and nose to lungs. Asthma
is caused generally due to allergies leading to inflammation of lungs.
GlaxoSmithKline Pharmaceuticals Limited and Novartis AG are
developing once-a-day combination products that are longer acting than
currently available drugs and more suitable for patients due to its advantage
of being taken only once a day.
Based on drug class, the global asthma market can be
categorized bronchodilators, combination therapies, mast cell stabilizers,
leukotriene antagonists and immunosuppressants. On the basis of route of
administration, the global market is segmented into oral, inhaled and other
route of administrations.
Make
Enquiry Before Buying the Report: https://www.psmarketresearch.com/send-enquiry?enquiry-url=asthma-market
Daily exposure to hazardous working environment, influx
of pollutants in the air, increase in population susceptible to indoor air
pollutants, increase in disposable income, increasing population of smokers,
improved healthcare facility, and growing aging population are some of other
the major factors that are driving the growth of asthma market. Factors that
are restraining the growth of asthma market are high cost of asthma treatment,
patent expiry of many best-seller brands and long treatment continuation.
Additionally, lack of diagnostic tools for reliable asthma diagnosis in young
children is also limiting the growth of global asthma market.
Some of the major competitors of global asthma market
are, Ono Pharmaceutical Co., Ltd., GlaxoSmithKline plc, Teva Pharmaceutical
Industries Ltd. Merck & Co., Inc., Astrazeneca plc, Sunovion
Pharmaceuticals, Inc., Novartis AG, Boehringer Ingelheim GmbH, Koninklijke
Philips N.V., and F. Hoffmann La-Roche Ltd.
About P&S
Intelligence
P&S Intelligence, a brand of P&S Market Research, is a provider
of market research and consulting services catering to the market information
needs of burgeoning industries across the world. Providing the plinth of market
intelligence, P&S as an enterprising research and consulting company,
believes in providing thorough landscape analyses on the ever-changing market
scenario, to empower companies to make informed decisions and base their
business strategies with astuteness.
Contact:
P&S Intelligence
Toll-free: +1-888-778-7886
(USA/Canada)
International: +1-347-960-6455
Email: enquiry@psmarketresearch.com
Immunotherapy Drugs Market Analysis by Stages, Drug Class, Company Profile, Phase of Development, Clinical Trial, Preclinical Research & Discovery Stage Insights
Pramod KmrDecember 11, 2018Clinical Trial, Company Profile, Drug Class, Immunotherapy Drugs Market Analysis by Stages, Phase of Development, Preclinical Research
3 comments
The global immunotherapy
drugs market valued $106.1 billion revenue in 2017 and is
projected to register a CAGR of 13.6% during the period 2018–2023. Surge in the
prevalence of chronic diseases, and thriving demand and development of
monoclonal antibodies (mAbs) are the key factors driving the market growth.
Checkpoint inhibitors and vaccines are the two
major types of immunotherapy drugs analyzed in the report. Of these, checkpoint
inhibitors held a larger share in the immunotherapy
drugs market, accounting for 66.3% in 2017. Checkpoint
inhibitors are the first preference for the treatment of chronic diseases, as
they provide better and effective treatment results. These drugs act directly
on site of action, without delaying the effect of medicine, and are thus being
highly adopted for the treatment of several diseases. Some of the major
checkpoint inhibitors brand available in the market are Humira,
Rituxan/MabThera, Herceptin, Remicade, and Enbrel.
Hospitals and clinics were the key end users in the
immunotherapy drugs market, with 81.0% contribution in 2017. The adoption of
immunotherapy drugs has been increasing in hospitals and clinics, owing to
growing patient population, increasing healthcare expenditure, and rising
prevalence of chronic diseases, leading to dominate the end-user segment.
North America was the largest immunotherapy drugs
market during the historical period, with more than 50.0% contribution in 2017.
This can be attributed to the increasing per capita healthcare spending, surging
geriatric population, rising prevalence of chronic diseases, and growing
presence of market players in the region. Furthermore, factors such as growing
research collaborations, increasing number of research laboratories, and
growing direct and indirect investments in research and development (R&D)
by pharmaceutical and biotechnology companies will also support the growth of
the regional market in the coming years.
Download Report Sample Copy at:
Globally, the rising prevalence of chronic diseases
is a major healthcare burden that effects high income nations as well as low
and middle-income countries (LMIC). The impact of these diseases can be
ascertained from the fact that cancer is estimated to lead to 9.6 million
deaths in 2018, as reported by the World Health Organisation (WHO). The
organisation further stated that around 70% of deaths from cancer occur in
LMIC.
Several drugs manufactured by market players for
the treatment of chronic diseases are under clinical trials. Thus, increasing
use of immunotherapy drugs to combat the rising prevalence of chronic diseases
is an important factor driving the market demand. Moreover, thriving demand and
development of mAbs, rise in the implementation of target therapy, and
increasing availability of biosimilars are also contributing to the growth of
the immunotherapy drugs market.
The report provides epidemiology analysis for cancer,
autoimmune and inflammatory diseases, and infectious diseases. According to the
International Agency for Research on Cancer (IARC) in 2018, 18.1 million people
are estimated to be suffering from cancer globally, which is expected to reach
29.5 million by 2040. Another study conducted by the American Medical
Association (AMA) between 2005–2015, reported that the incident of cancer cases
increased by 33% during this period, of which 16.4% of the cases were due to
aging population.
Make
Enquiry Before Buying the Report: https://www.psmarketresearch.com/send-enquiry?enquiry-url=immunotherapy-drugs-market
The report also covers pricing and reimbursement scenario
for immunotherapy drugs on the universal level and for major countries such as
the U.S., Belgium, the U.K., France, Italy, Spain, Japan, China, and Australia.
For instance, a reimbursement scenario in the U.K. has impacted the cost of the
drugs. Keytruda is an immunotherapy drug used for the treatment of melanoma,
non-small cell lung cancer (NSCLC), head and neck squamous cell cancer (HNSCC),
urothelial carcinoma, gastric cancer, and cervical cancer. Keytruda generally
costs up to $84,000 to the patients. To reduce the cost of this drug, the
National Health Service (NHS) England; a publicly funded national healthcare
system, and Merck & Co. Inc. entered into an agreement in June 2018, to
reimburse the cost of this drug and provide it for routine use as per the
National Institute for Health and Care Excellence (NICE) recommendations. NICE
recommends NHS to provide reimbursements for this drug and make it affordable
for the patients.
Some of the other leading players operating in the
global immunotherapy drugs market are F. Hoffmann-La Roche Ltd., AbbVie Inc.,
AstraZeneca PLC, Merck & Co. Inc., GlaxoSmithKline plc, Novartis International
AG, Johnson & Johnson, Amgen Inc., Bristol-Myers Squibb Company, Eli Lilly
and Company, Sanofi, Medigene AG, C. H. Boehringer Sohn AG & Co. KG, Takeda
Pharmaceutical Company Limited, and Celgene Corporation.
MARKET SEGMENTATION
By Therapy Area
By Therapy Area
·
Cancer
o Solid Tumor
o Malignant
·
Autoimmune
& Inflammatory Diseases
·
Infectious
Diseases
·
Others
By Type of Drug
·
Monoclonal
Antibodies
·
Adult
Vaccines
o Preventive Vaccines
o Therapeutic Vaccines
·
Checkpoint
Inhibitors
·
Interferons
Alpha & Beta
·
Interleukins
·
Others
By End User
·
Hospitals
·
Clinics
·
Others
Geographical Segmentation
·
North
America
o U.S.
o Canada
·
Europe
o Germany
o U.K
o France
o Italy
o Spain
o Rest of Europe
·
Asia-Pacific
o China
o India
o Japan
o Rest of Asia-Pacific
·
Latin
America
o Brazil
o Mexico
o Rest of Latin America
·
Middle
East & Africa (MEA)
Breast Cancer Market Comprehensive Analysis of Market Trends, Technological Advancements, Company Profile and Growth Opportunities
Pramod KmrNovember 19, 2018Breast Cancer Market, Breast Cancer Market Share, Breast Cancer Market Size, Demand, Growth, Share
No comments
Cancer is a disease
characterized by uncontrolled growth of cell. There are about 100 different
types of cancer and each is classified by the type of cell where it occurs and
affects. Breast cancer is mostly prevalent in women, however, breast cancer
in men is rare. It is frequently diagnosed in aged women and one of the leading
causes of death among them. Some of the most common types of breast cancer are
ductal carcinoma in situ (DCIS), lobular carcinoma and invasive ductal
carcinoma.
DCIS, also known as
intraductal carcinoma, begins in the lining of the milk ducts. Milk ducts are thin
tubes carrying milk from lobules of the breast to the nipple. Lobule carcinoma
originates in the lobules or milk glands of the breast. Invasive ductal
carcinoma is the most common type of breast cancer. It starts in a milk duct of
the breast, ruptures through the wall of the duct and grows into the fatty
tissue of the breast. It spreads to other parts of body through bloodstream.
North America accounts
the largest global breast cancer market followed by Europe. The U.S., followed
by Canada, is the largest market for breast cancer in North America. Key
driving factor for this market is increasing prevalence of breast cancer in the
region. Germany, France and the U.K. are some of the largest markets for breast
cancer in Europe region. However, Asia-Pacific represents the fastest growing
region in the global breast cancer market. This is due to improving healthcare
infrastructure and increasing awareness among people about breast cancer. In
developing countries, such as China and India, government has launched several
programs and initiatives which increase awareness about the disease. It has led
to significant rise in demand of breast cancer diagnostics and therapeutics for
disease management. In addition, less stringent wages and availability of
skilled labor attracts manufacturing companies to invest in developing
countries.
Make Enquiry Before Buying the Report: https://www.psmarketresearch.com/send-enquiry?enquiry-url=-breast-cancer-market
Increasing prevalence of
the disease is a key driving factor for the global breast cancer market.
Increasing awareness among people about the disease and rising number of
geriatric women around the world are also supporting the growth of global
breast cancer market. In addition, increased research in the field of oncology
and development of biomarker has also fueled the growth of global breast cancer
market. Increasing demand of advanced therapeutic drugs and extensive drug
pipeline holds immense potential to the growth of the global breast cancer
market.
Some of the major
competitors in the market are Astrazeneca PLC, F. Hoffmann-La Roche Ltd, Eli
Lilly and Company, Novartis AG, Sanofi-Aventis. Pfizer, Inc., Bristol-Myers
Squibb Company, Bayer AG, GlaxoSmithKline plc and Teva Pharmaceutical
Industries Ltd.
Bile Duct Cancer Therapeutics Market Has Been Classified on the Basis of Disease Indication, Treatment Type and Geography
Pramod KmrNovember 08, 2018Bile Duct Cancer Therapeutics Market, Demand, Growth, Outlook, Share, Size
2 comments
Bile duct cancer is also known as
cholangiocarcinoma. It involves the presence of mutated epithelial cells
originated in the bile ducts. However, the cause of bile duct cancer
(cholangiocarcinoma) is not certain. There are some factors that can increase
the chances of developing bile duct cancer (cholangiocarcinoma).
The most common
symptoms of bile duct cancer (cholangiocarcinoma) include abdominal pain,
abnormal liver function, generalized itching, weight loss, discoloration of
stool and urine, etc. The risk factor of bile duct cancer (cholangiocarcinoma)
include liver fluke infections, cholangitis and exposure to thorium dioxide.
According to American Society of Clinical Oncology (ASCO), less than 3,000
people are affected with the disease, every year, in the U.S. Also, according
to Cancer Research UK, about 1,600 people are affected by the disease, every
year, in the U.K. The existing treatment options for bile duct cancer
(cholangiocarcinoma) are mainly dominated by generics and off-label drugs, and
provide only symptomatic relief.
The global bile duct cancer therapeutics market has been classified on
the basis of disease indication, treatment type and geography. Based on disease
indication, the global bile duct cancer therapeutics market has been segmented
into perihilar (hilar) bile duct cancers, distal bile duct cancers, and
intrahepatic bile duct cancers. Based on treatment type, the global bile duct
cancer therapeutics market has been segmented into chemotherapy, chemoradiation
and stent insertion. Based on region, the global market has been segmented into
Latin America, North America, Asia-Pacific, Middle East & Africa, and
Europe.
Make Enquiry
Before Buying the Report: https://www.psmarketresearch.com/send-enquiry?enquiry-url=bile-duct-cancer-therapeutics-market
Geographically,
North America has been the largest market for bile duct cancer therapeutics.
The growth of the regional market can be attributed to adequate reimbursement
policies, greater awareness toward health care and advanced healthcare
facilities. The Asia-Pacific and European markets for bile duct cancer
therapeutics are projected to record strong CAGRs, over the forecast period.
Some of the key players in the global bile duct cancer therapeutics
market include, Bayer, AG, Delcath Systems Inc., Senhwa Biosciences, Inc., PCI
Biotech, Inc., ASLAN Pharmaceuticals, Inc., RedHill Biopharma Ltd. and Halozyme
Therapeutics, Inc. among several others.


















